Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE III, DOUBLE-BLIND, RANDOMIZED PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECTS OF DALCETRAPIB ON CARDIOVASCULAR (CV) RISK IN A GENETICALLY DEFINED POPULATION WITH A RECENT ACUTE CORONARY SYNDROME (ACS): THE DAL-GENE TRIAL

Intervention/treatment:
DALCETRAPIB
Medical condition:
ACUTE CORONARY SYNDROME
Protocol code:
DAL-301
Control number:
190799
Status:
Closed
Approved:
January 20, 2016
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT02525939
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
45 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Dr. Don Black, Chief Medical Officer
Organization
DalCor Pharmaceuticals
Phone:
‭+1 (609) 613-6637‬
Sponsor
DALCOR PHARMA UKLTD, SWISS BRANCH

Locations

Alberta

Research Site
Calgary, Alberta
Research Site
Edmonton, Alberta

British Columbia

Research Site
Vancouver, British Columbia
Research Site
Victoria, British Columbia

Manitoba

Research Site
Winnipeg, Manitoba

New Brunswick

Research Site
Moncton, New Brunswick, H1T 1C8
Research Site
Saint John, New Brunswick

Newfoundland and Labrador

Research Site
St. John's, Newfoundland and Labrador

Nova Scotia

Research Site
Bridgewater, Nova Scotia

Ontario

Research Site
Burlington, Ontario
Research Site
Cambridge, Ontario
Research Site
Greater Sudbury, Ontario
Research Site
Hamilton, Ontario
Research Site
London, Ontario
Research Site
Newmarket, Ontario
Research Site
Ottawa, Ontario
Research Site
Peterborough, Ontario
Research Site
Scarborough Village, Ontario
Research Site
Thunder Bay, Ontario
Research Site
Toronto, Ontario

Quebec

Institut de Cardiologie de Montreal
Montreal, Quebec, H1T 1C8
Research Site
Chicoutimi, Quebec
Research Site
Granby, Quebec
Research Site
Laval, Quebec
Research Site
Lévis, Quebec
Research Site
Longueuil, Quebec
Research Site
Montreal, Quebec
Research Site
Saint George, Quebec
Research Site
Saint-Charles-Borromée, Quebec
Research Site
Saint-Jean-sur-Richelieu, Quebec
Research Site
Saint-Jérôme, Quebec
Research Site
Sherbrooke, Quebec
Research Site
Terrebonne, Quebec
Research Site
Thetford-Mines, Quebec
Research Site
Trois-Rivières, Quebec
Research Site
Québec, Quebec

Results

See the results from the trial NCT02525939. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?